Effects of Intermittent Energy Restriction on Intra-Abdominal Fat and the Gut Microbiome: A Randomized Trial
试验速览
- 阶段
- 不适用
- 状态
- 暂停
- 发起方
- 入组人数
- 260
- 试验地点
- 2
- 主要终点
- Dual-energy X-ray absorptiometry (DXA) scan for total adiposity
研究概览
简要总结
Intermittent energy restriction (IER) may have important advantages over daily energy restriction (DER) in producing sustained weight loss and reducing cancer risk. IER is already being promoted with limited evidence, thus, additional evidence is urgently needed from rigorously conducted clinical trials. IER has been proposed to invoke a greater metabolic shift to fat metabolism than DER and preferentially reduce central obesity. The Investigators adapted the IER and the Mediterranean diet (MED) approach which have been recommended as a healthy weight-loss diet in the management of non-alcoholic fatty liver disease, for an ethnically diverse population. The effectiveness was compared to an active comparator (DASH diet) in reducing overall and visceral adiposity in a randomized trial among 60 middle-aged adults with visceral obesity. This 12-week pilot demonstrated the feasibility and safety of IER and the culturally-adapted MED [NCT03639350]. The six-month randomized trial will demonstrate the superiority of IER over DER in reducing fat and total fat mass, and in improving cancer-related biomarkers and gut microbiome functions. This longer trial, to confirm safety and superiority of IER over DER in reducing VAT and liver fat will expand our understanding of adherence to IER and its effect on the gut microbiome as a possible mediator of systemic inflammation. The Investigators will conduct a 24-week randomized trial of IER+MED vs. MED/DER among 260 middle-aged adults of East-Asian, Native Hawaiian and other Pacific Islanders or White ethnicity with high VAT. The primary research question is whether a diet plan combining IER and the MED dietary pattern will be superior to MED/DER in reducing abdominal MRI-measured visceral and liver fat and dual-energy X-ray absorptiometry (DXA) measured total adiposity. The Healthy Diet and Lifestyle Study II (HDLS2) will recruit 312 men and women from the general population with VAT at or above the population-median (men: ≥90 cm2; women ≥80 cm2) and randomize them to the IER+MED or MED/DER diet (156 per group). The IER+MED group will follow IER for two consecutive days (70% energy restriction) and total energy MED diet for the other five days of the week, reaching an overall 20% energy restriction. The MED/DER group will be prescribed a 20% daily energy restriction. With an expected attrition rate of ~16% (10% in Pilot), the investigators expect 130 participants per group to complete the study.
详细描述
Goal: This study proposes a 24-week randomized trial of intermittent energy restriction (IER) and the Mediterranean diet (MED), IER+MED, compared to daily energy restriction (MED/DER) among 260 middle-aged adults of East-Asian, Native Hawaiian and other Pacific Islanders or white ethnicity with high visceral fat (VAT) and liver fat.
- To investigate whether a diet plan combining IER+MED will be superior to MED/DER in reducing abdominal visceral and liver fat and total adiposity among a multiethnic, at-risk, adult population. The Healthy Diet and Lifestyle Study II (HDLS2) plans to recruit 312 men and women from the general population with VAT at or above the population-median (men: ≥90 cm2; women ≥80 cm2) and randomize them to the IER+MED or MED/DER diet (156 per group). The IER+MED group will follow IER for two consecutive days (70% energy restriction) and a total energy MED diet for the other five days of the week, reaching an overall 20% energy restriction. The MED/DER group will be prescribed a 20% daily energy restriction. The expected attrition rate is ~16%, thus 130 participants per group are expected to complete the study.
- To determine if the IER+MED compared to the MED/DER influences intermediate markers: cancer-related blood biomarkers and the gut microbial community structure and function.
- To assess behavioral predictors of adherence to the prescribed IER+MED and DER/MED. To test modifications to psychosocial constructs being associated with adherence differently between IER+MED and MED/DER.
Design: The HDLS2 is a parallel, randomized, trial to compare the effects of two diets over 24-weeks: the IER+MED diet pattern vs. the MED/DER daily energy restriction diet pattern. For randomization, biostatisticians will prepare a blocked randomization schedule, stratified by men/women, the three ethnic groups, age <50 and 50+ y for men, menopausal status for women (based on any periods in the last 12 months), and two VAT groups (high, 80-150 cm2 or very high, ≥150 cm2). The randomization procedure will be conducted using opaque, sealed, sequentially numbered envelopes each containing assignment with equal probability to one of the two dietary interventions. The participants and measurement staff will be masked from the moniker of the assigned dietary intervention. The dietitians will coordinate and conduct the intervention activities using four face to face meetings (or an alterative if needed), and 12 remote meetings using phones or communication platforms (eg. Zoom). Every effort will be made for each participant to stay with the same dietitian. Enrollment of 156/study arm and completion of the intervention activities will take place over 3.5 years.
The research will be carried out in the University of Hawaii Cancer Center (UHCC) Translational Research Clinic, Nutrition Education Center, and Metabolic Kitchen, as well as the University of Hawaii (UH) Magnetic Resonance Imaging (MRI) Research Center. Each of these units have approved common guidelines addressing specific guidance for the coronavirus disease (COVID-19) screening of staff and research participants prior to the visit, upon arrival to the clinic, entry to the clinic, and post appointment guidelines.
Recruitment, clinic, and imaging staff will be blinded to randomization and intervention activities. Likewise, other than baseline demographic information, the intervention staff (dietitians) will be blinded to assessment measures of the study participants (with the exception of body weight, which is needed for the dietary prescriptions). Volunteers will be recruited among Oahu residents using advertising, media exposure, community and workplace presentations, and referrals from clinical partners. Main eligibility criteria were informed by the pilot study. Assuming a ~16% drop-out rate to yield 260 participants completing the 6-month intervention. The first recruits will start in October 2021, with the goal of recruiting 16 participants/month (except mid Nov through first week of Jan).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
盲法说明
Participants will be provided with healthful dietary information but will not be told what diets their diet plans are based on. Participants in the IER+MED diet group will be told they are on diet plan 1 and participants in the MED/DER diet group will be told they are on diet plan A. The dietitians will know which diet plan each participant is on, however; all other clinic staff who assess outcome measures will be blinded to each participant's diet group.
入排标准
- 年龄范围
- 35 Years 至 69 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 35-69 years old
- •BMI between 25-40 kg/m2
- •Currently non-smoking
- •No serious health issues
- •Fully vaccinated for COVID-19
- •Normal blood chemistry profile
- •East Asian (Chinese, Japanese, Korean), Filipino, Native Hawaiian/other Pacific Islander or white/European ancestry
- •Non-drinkers / low habitual drinkers, i.e., men ≤15 drinks per week, women ≤10 drinks per week
- •Volunteers living on the island of Oahu
- •For peri-menopausal women, the investigators will require that they had their last period at least 1 year before baseline)
- •DXA VAT ≥90 cm2 for men and ≥80 cm2 for women
- •Able to read, speak, and write in English
排除标准
- •Pregnancy
- •Contraindication to MR imaging (e.g. pacemaker, claustrophobia, metal implants)
- •Previous surgery to remove any part of the small intestine, colon or rectum (e.g.
- •ileostomy or colectomy) or an amputation of a leg or arm.
- •For women, taking any anti-estrogen medications (e.g tamoxifen, Nolvadex, Istubal, Valodex)
- •For men, taking any anti-androgen medications (e.g., Eulexin (flutamide); Anandron or Nilandron (nilutamide); Casodex (bicalutamide); Proscar or Propecia (finasteride); Avodart (dutasteride); or bexlosteride, izonsteride, turosteride, episteride).
- •Diagnosis of Type 1 diabetes or Type 2 diabetes and taking insulin for treatment
- •Diagnosis of thyroid conditions under treatment with hormones or medications.
- •Serious health issues such as dialysis, organ transplant, celiac disease, Crohn's disease, chronic liver disease, active case of hepatitis B or C, chronic kidney disease, or any condition that, in the opinion of the investigator, is a contraindication to participation.
- •Previous problem with fasting blood collection
- •Cannot exercise (walk) for up to 1hr/day
- •Deferral Criteria :
- •Volunteers with the following conditions will be called back after the specified duration:
- •Treatments in past 6 months: chemotherapy or radiation of abdomen/pelvis; corticosteroid hormones; prescription weight loss drugs; estrogen/androgen receptor blockers
- •Substantial weight change (>20lbs) in past 6 months
- •Antibiotic use in past 3 months
- •Colonoscopy, sigmoidoscopy, colon irrigation/bowel cleaning in the past 3 months
- •MRI/CAT scan with contrast in the past 2 weeks
结局指标
主要结局
Dual-energy X-ray absorptiometry (DXA) scan for total adiposity
时间窗: Week 24
To investigate whether the diet plan IER+MED will be superior to MED/DER in reducing DXA-measured total adiposity.
Abdominal magnetic resonance imaging (MRI) to measure visceral fat and liver fat
时间窗: Week 24
To investigate whether a diet plan combining intermittent energy restriction (IER) and a Mediterranean diet (MED) dietary pattern (IER+MED) will be superior to a MED diet and daily energy restriction (DER) (MED/DER) in reducing abdominal MRI-measured visceral and liver fat.
次要结局
- DXA scan for total adiposity at week 48 (24 weeks post trial)(Week 48)
- Measured body weight at week 48 (24 weeks post trial).(Week 48)
- Measured waist- and hip-circumferences at end of trial.(Week 24)
- Measured body weight at end of trial(Week 24)
- Computed body mass index (BMI) at end of trial.(Week 24)
- Computed body mass index (BMI) (24 weeks post trial)(Week 48)
- Fat mass, computation of fat mass using completed measurement values (24 weeks post trial)(Week 48)
- Measured waist- and hip-circumferences (24 weeks post trial)(Week 48)
- Fat mass, computation of fat mass using completed measurement values at end of trial.(Week 24)
